Track topics on Twitter Track topics that are important to you
Herceptin is a targeted therapy approved for the treatment of people with certain HER2+ cancers. HER2+ cancer cells have more HER2 receptors (a particular protein found on the surface of cells) than normal cells. HER2+ cancer is considered aggressive because it grows and spreads quickly.
Adjuvant Breast Cancer
Herceptin is approved for the treatment of early-stage breast cancer that is Human Epidermal growth factor Receptor 2-positive (HER2+) and has spread into the lymph nodes, or is HER2+ and has not spread into the lymph nodes. If it has not spread into the lymph nodes, the cancer needs to be estrogen receptor/progesterone receptor (ER/PR)-negative or have 1 high risk feature.
Metastatic Breast Cancer
Herceptin has 2 approved uses in metastatic breast cancer:
Taxol is a registered trademark of Bristol-Myers Squibb Company.
Metastatic Gastric/GEJ Cancer
Herceptin is approved, in combination with chemotherapy (cisplatin and either capecitabine or 5-fluorouracil), for the treatment of HER2+ metastatic cancer of the stomach or gastroesophageal junction (where the esophagus meets the stomach) in patients who have not received prior treatment for their metastatic disease.
For further information open - http://www.herceptin.com/
Drug maker: Roche
Indication(s): HER2-positive breast cancer and HER2-positive metastatic gastric cancer
2012 sales: $6.397 billion (CHF 5.889 billion)4